Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter ...

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report published on Thursday,Benzinga reports. Several other equities analysts have also ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have been given an average rating of “Moderate Buy” by the ten analysts that are presently covering the company, Ratings reports.

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in ...

A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based ...